Dr. Richard Furman

A powerful new set of scientific tools developed by Weill Cornell Medicine and New York Genome Center (NYGC) researchers enables them to track the molecular evolution of cancers. 

Bob Azopardi thought he only had months to live. After a routine physical, the 49-year-old was diagnosed with a type of cancer called chronic lymphocytic leukemia. 

Ongoing monitoring for genetic changes in chronic lymphocytic leukemia (CLL) during targeted treatment may allow clinicians to adjust patients’ treatments as the cancer evolves, according to a study in Nature Communications led by Weill Cornell Medicine and New York Genome Center scientists.

For decades, Weill Cornell has been a leader in the research revolution that's making lymphoma a survivable disease.